NEXGEL, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Acquisition (Tables)

Acquisition (Tables)

3 Months Ended

Mar. 31, 2024

Schedule of Unaudited Pro-Forma Results of Operations

	2024			2023
	March 31, March 31,
	2024			2023
Revenues, net	$	1,266		$	1,140
Net loss allocable to common shareholders	$	(871	)	$	(717	)
Net loss per share	$	(0.15	)	$	(0.13	)
Weighted average number of shares outstanding		5,982,062			5,586,326

Kenkoderm Acquisition [Member]

Business Acquisition [Line Items]

Schedule of Business Acquisitions

The table below shows a preliminary analysis for the Kenkoderm acquisition ($ in thousands):

Schedule of Business Acquisitions

Provisional purchase consideration at preliminary fair value:
Purchase price	$	547
Contingent consideration liability		439
Amount of consideration	$	986
Assets acquired and liabilities assumed at preliminary fair value
Inventory		56
Product/technology related intangibles		77
Marketing related intangibles		36
Net tangible assets acquired	$	169

Total net assets acquired	$	169
Consideration paid		986
Preliminary goodwill	$	817

CG Labs [Member]

Business Acquisition [Line Items]

Schedule of Business Acquisitions

The recorded assets acquired and liabilities assumed in connection with the formation of the JV based on their estimated fair values as of the March 1, 2023. The purchase price allocation is as follow ($ in thousands):

Schedule of Business Acquisitions

Purchase consideration at fair value:
Cash contributed by the Company	$	500
Noncontrolling interest portion of CG Labs contributed business		500
Amount of consideration	$	1,000
Assets acquired and liabilities assumed at fair value
Cash contributed by the Company		500
Fixed assets		213
Product/technology related intangibles		217
Marketing related intangibles		70
Net tangible assets acquired	$	1,000

Total net assets acquired	$	1,000
Consideration paid		1,000
Goodwill	$	-